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The aim of the study was to evaluate the usability of three diagnostic procedures for the detection of respiratory syncytial virus
in clinical samples. Therefore, the FDA cleared CE marked NOWH RSV ELISA, the NucliSENSH EasyQ RSV A+B NASBA, and a
literature based inhouse RT-PCR protocol were compared for their relative sensitivities. Thereby, NASBA turned out to be the
most sensitive method with a total number of 80 RSV positive samples out of a cohort of 251 nasopharyngeal washings from
patients suffering from clinical symptoms, followed by the inhouse RT-PCR (62/251) and ELISA (52/251). Thus, NASBA may serve
as a rapid and highly sensitive alternative for RSV diagnostics.
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INTRODUCTION
Despite an increasing number of newly detected respiratory
pathogen the human Respiratory syncytial virus (RSV) remains
the single most prevalent etiologic agent in pediatric viral
respiratory tract infection [1,2,3]. RSV is responsible for the
majority of episodes of acute wheezing triggered by infection [4],
bronchiolitis [5] and pneumonia [6] predominantly during the first
24 months of life. An estimated percentage of about 1–2% of all
RSV-infected children require hospital care. The RSV-related
hospitalization rate and the risk of severe complications are
increased in prematurely born infants with chronic lung disease
(CLD) [7] and in children with hemodynamically relevant
congenital heart disease (CHD) [8,9], other forms of chronic lung
disease or severe neuromuscular impairment [2]. Forster and
coworkers estimated (95% confidence interval) a total of 26,524
(23,812–29,432) RSV-related hospitalizations per year in children
under 3 years of age in Germany (i.e. 38% of all pediatric
hospitalizations for viral lower respiratory tract infection) [10].
The same group calculated J2.772 as median total costs per
hospitalised RSV-Infection [11,12,13]. Others recently calculated
even higher costs [14]. Specific therapeutic agents with proven
efficacy against RSV are still not available [1,5]. Meticulous hand
hygiene after patient contact together with other barrier
precautions and rapid laboratory diagnostic are considered to be
of utmost importance for the prevention of nosocomial transmis-
sion [16,17]. Rapid laboratory detection of RSV is mainly
performed by ELISA [17,18] or by the use of nucleic acid
amplification and detection methods. The latter methodology
includes a high number of RT-PCR protocols, but for reasons of
quality assurance in quality management systems the need for
standardized nucleic acid amplification procedures with quality
marks like the CE mark increases more and more. Recently, the
NucliSENS EasyQ RSV A/B (bioMerieux, Nu ¨rtingen, Germany),
a CE-labeled Nucleic acid sequence based amplification (NASBA)
based kit for the rapid detection of RSV, became available. In
search for options to optimize the rapid laboratory diagnostics of
RSV we have compared this NASBA method with a published
RT-PCR protocol and a rapid ELISA, the latter both used in our
routine procedures for the detection of RSV.
MATERIALS AND METHODS
The patient cohort consisted of a total number of 251 pediatric
patients hospitalized with respiratory tract infection. Only one
clinical sample per patient was included in the study, resulting in a
total number of 251 nasopharyngeal aspirates. These aspirates
were used freshly for all subsequent procedures and were not
frozen before usage. All specimens were previously tested negative
by PCR or RT-PCR as previously described [16,2] for any of the
following viruses: human bocavirus, human metapneumovirus,
Influenzaviruses A and B, and human coronaviruses NL63,
HKU1, SARS, OC43, and 229E. Additional tests to detect
Rhinoviruses, Adenoviruses, Parainfluenzaviruses, or bacteria,
were not performed in our laboratory. The main focus of the
present study was to evaluate the sensitivity and specificity of the
NASBA method and the rapid ELISA compared to RT-PCR.
Native samples were tested by the FDA cleared CE marked
NOWH RSV ELISA (Inverness Medical, Cologne, Germany).
NOWH RSV ELISA tests were carried out strictly following the
manufacturer’s protocol and considered positive according to the
manufacturer’s guidelines. For NSABA and RT-PCR RNA was
automatically extracted by the NucliSENSH easyMAG
TM (bio-
Merieux, Nu ¨rtingen, Germany) using the manufacturer’s extrac-
tion protocol for nasopharyngeal specimen, using 100 mlo f
specimen preincubated for 30 min at 37uC with 10 ml DNase
and 12 ml DNase buffer (Promega, Germany). Subsequent
NASBA reactions were carried out using the NucliSENSH EasyQ
(bioMerieux, Nu ¨rtingen, Germany) system strictly following the
manufacturer’s guidelines. RNA used for RT-PCR was extracted
as described above. RT-PCR was performed essentially as
previously described by Mentel and coworkers [19]. Briefly,
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Transcriptase (Roche, Mannheim, Germany) for 30 min at 42uC
with primers F1 Forward primer GTTGGATCTGCAATCGC-
CAGTGGC and F2 Reverse primer GTACATAGAGGGGATG-
TGTG, followed by a five minute denaturation step at 99uC. First
round PCR was performed with primers F1 and F2 (165994uC;
40630094uC, 30054uC, 45072uC; 165972uC) using the Expand
High Fidelity PCR system (Roche, Mannheim, Germany) according
the producer’s recommendation. The second round of PCR was
performed with the identical temperature profile but with nested
primers F3 Forward primer TTAACCAGCAAAGTGTTAGA and
F4 Reverse primer TTTGTTATAGGCATATCATTG.
RESULTS AND DISCUSSION
The results are summarized in table 1. From the 251 specimen 52
(20.7%) were tested positive for RSV by NOWH RSV ELISA
(Inverness Medical, Cologne, Germany), 62 (24.7%) were tested
positive for RSV by RT-PCR, and 80 (31.9%) were tested positive
for RSV by NucliSENSH EasyQ NASBA (bioMerieux, Nu ¨rtingen,
Germany). Thus, as the highest sensitivity was observed for the CE
marked NucliSENSH EasyQ, this relative sensitivity was set to
100%. Thereby it was assumed that with NucliSENSH EasyQ
according to the CE marked guarantee a sensitivity and specificity
of this test of 99% as earlier described [20]. In relation to the
positive test results obtained with the NucliSENSH EasyQ
NASBA, the relative sensitivity of the RT-PCR was 77,5%
compared to 65% obtained with the NOWH RSV ELISA.
A total number of 43 (17.1%) samples were tested positive for
RSV by all methods, 16 samples (6.37%) were tested positive for
RSV by both RT-PCR and ELISA but not by ELISA, 4 samples
(1.59%) were tested RSV positive by RT-PCR and ELISA but not
by NASBA, 1 sample (0.4%) was tested RSV positive only by RT-
PCR, 4 samples (1.59%) were tested RSV positive only by ELISA,
and 17 samples (6.77%) were tested RSV positive only by NASBA.
The overall accordance of all techniques was 53.75%, the accord-
ance of RT-PCR and NASBA was 76.25%, the accordance of
NASBA and ELISA was 60%, and the accordance of RT-PCR and
ELISA was 78.69%. The negative predictive values for were 97.1%
for NASBA, 83.4% for ELISA, and 87.8% RT-PCR, the positive
predictive values were 94.1% for NASBA, 92.9% for ELISA, and
100% RT-PCR (table 2). The results showed that from the three
tested methods for molecular diagnosis of RSV the NucliSENSH
EasyQ NASBA (bioMerieux, Nu ¨rtingen, Germany) detected the
most RSV positive samples in a cohort of 251 nasopharyngeal
samples of pediatric patients hospitalized with respiratory disease.
Taking into account data published in the manufacturer’s
manuals and on their respective websites, it can be assumed that
the specificity of both NucliSENSH EasyQ NASBA and the
NOWH RSV ELISA is very high. Furthermore, as demonstrated
last year by Manji and coworkers, the NucliSENSH EasyQ
NASBA assay specifity has a positive sample value of $1.100 with
an acceptable IC value of $1.100 [21]. Thereby, the absolute
assay specifity turned out to be $95%. For the NOWH RSV
ELISA Cruz et al. [22] determined that the sensitivity was 81%
and specificity 93.2%. Moreover, with our in house RT-PCR we
have not yet any false positive as all detections were confirmed by
sequencing (Simon, Schildgen et al., unpublished data). It is
commonly known that antibody based methods ELISA like for
detection of RSV in clinical samples is less sensitive than nucleic
acid amplification techniques [23]. However, the rapid results are
of high importance for clinicians in order to initiate therapy and/
or isolation of the patients in order to avoid nosocomial outbreaks.
In this earlier study which solely compared rapid ELISA methods,
the NOWH RSV ELISA was found to be the most sensitive at least
for the cohort of pediatric patients [17] with hands on time of
about 10 to 20 min. However, taken into account the higher
relative sensitivity and the acceptable predictive values accompa-
nied by short hands on time and final results in nearly of 90 min,
the NucliSENSH EasyQ NASBA may serve alternative method as
it is both a fast but also a highly sensitive method. It thus should be
taken into account whenever rapid and sensitive RSV diagnostics
are required, such as in clinical setting involving high risk patients
for which nosocomial outbreaks may be a fatal event.
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